Trial Profile
Effect of inhaled vilanterol trifenatate/fluticasone furoate on breathing pattern, dyspnoea and respiratory muscle function in severe chronic obstructive pulmonary disease
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 12 Nov 2015
Price :
$35
*
At a glance
- Drugs Vilanterol/fluticasone furoate (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- 12 Nov 2015 New trial record